Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections.
METHODS: This multicenter retrospective study examined nAMD eyes receiving monthly aflibercept injections switched to faricimab administered monthly up to 4 injections followed by injections at a minimum of 2-month intervals as per drug labeling. Data regarding age, sex, number of previous injections, treatment intervals, and best-corrected visual acuity (BCVA) were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured by optical coherence tomography.
RESULTS: The study included 130 eyes of 124 patients. At 6 months, 53 eyes (40.8%) continued on faricimab treatment (Group 1), while 77 eyes (59.2%) discontinued faricimab for various reasons (Group 2) the most common being worse exudation. There were no significant differences between the two groups at baseline. In Group 1, CRT and SFCT significantly decreased at 1 month (P = 0.013 and 0.008), although statistical significance was lost at 6 months (P = 0.689 and 0.052). BCVA and maximal PED height showed no significant changes; however, mean treatment intervals were extended from 4.4 ± 0.5 weeks at baseline to 8.7 ± 1.7 weeks at 6 months (P < 0.001) in Group 1. No clear predictors of response were identified.
CONCLUSION: Switching from aflibercept to faricimab allowed for extension of treatment intervals from monthly to bimonthly in roughly 40% of eyes, suggesting that faricimab may be considered in refractory nAMD cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:262 |
|---|---|
| Enthalten in: |
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie - 262(2024), 1 vom: 30. Jan., Seite 43-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kataoka, Keiko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 24.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00417-023-06222-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361664354 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361664354 | ||
| 003 | DE-627 | ||
| 005 | 20240124231928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00417-023-06222-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM361664354 | ||
| 035 | |a (NLM)37668741 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kataoka, Keiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections | ||
| 520 | |a METHODS: This multicenter retrospective study examined nAMD eyes receiving monthly aflibercept injections switched to faricimab administered monthly up to 4 injections followed by injections at a minimum of 2-month intervals as per drug labeling. Data regarding age, sex, number of previous injections, treatment intervals, and best-corrected visual acuity (BCVA) were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured by optical coherence tomography | ||
| 520 | |a RESULTS: The study included 130 eyes of 124 patients. At 6 months, 53 eyes (40.8%) continued on faricimab treatment (Group 1), while 77 eyes (59.2%) discontinued faricimab for various reasons (Group 2) the most common being worse exudation. There were no significant differences between the two groups at baseline. In Group 1, CRT and SFCT significantly decreased at 1 month (P = 0.013 and 0.008), although statistical significance was lost at 6 months (P = 0.689 and 0.052). BCVA and maximal PED height showed no significant changes; however, mean treatment intervals were extended from 4.4 ± 0.5 weeks at baseline to 8.7 ± 1.7 weeks at 6 months (P < 0.001) in Group 1. No clear predictors of response were identified | ||
| 520 | |a CONCLUSION: Switching from aflibercept to faricimab allowed for extension of treatment intervals from monthly to bimonthly in roughly 40% of eyes, suggesting that faricimab may be considered in refractory nAMD cases | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aflibercept | |
| 650 | 4 | |a Angiopoietin-2 | |
| 650 | 4 | |a Faricimab | |
| 650 | 4 | |a Neovascular age-related macular degeneration | |
| 650 | 4 | |a Vascular endothelial growth factor | |
| 650 | 7 | |a aflibercept |2 NLM | |
| 650 | 7 | |a 15C2VL427D |2 NLM | |
| 650 | 7 | |a faricimab |2 NLM | |
| 650 | 7 | |a Receptors, Vascular Endothelial Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 700 | 1 | |a Itagaki, Kanako |e verfasserin |4 aut | |
| 700 | 1 | |a Hashiya, Nozumu |e verfasserin |4 aut | |
| 700 | 1 | |a Wakugawa, Sorako |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Mukai, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Honjyo, Jyunichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Maruko, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kawai, Moeko |e verfasserin |4 aut | |
| 700 | 1 | |a Miyara, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Terao, Nobuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Wakatsuki, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Onoe, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Ryusaburo |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Sekiryu, Tetsuju |e verfasserin |4 aut | |
| 700 | 1 | |a Iida, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Annabelle A |e verfasserin |4 aut | |
| 700 | 0 | |a for Japan AMD Research Consortium (JARC) |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Makiko |e investigator |4 oth | |
| 700 | 1 | |a Yamamoto, Akiko |e investigator |4 oth | |
| 700 | 1 | |a Kataoka, Keiko |e investigator |4 oth | |
| 700 | 1 | |a Okada, Annabelle A |e investigator |4 oth | |
| 700 | 1 | |a Itagaki, Kanako |e investigator |4 oth | |
| 700 | 1 | |a Ogasawara, Masashi |e investigator |4 oth | |
| 700 | 1 | |a Honjyo, Junichiro |e investigator |4 oth | |
| 700 | 1 | |a Mukai, Ryo |e investigator |4 oth | |
| 700 | 1 | |a Sekiryu, Tetsuju |e investigator |4 oth | |
| 700 | 1 | |a Hashiya, Nozomu |e investigator |4 oth | |
| 700 | 1 | |a Maruko, Ichiro |e investigator |4 oth | |
| 700 | 1 | |a Hasegawa, Taiji |e investigator |4 oth | |
| 700 | 1 | |a Kawai, Moeko |e investigator |4 oth | |
| 700 | 1 | |a Maruko, Ruka |e investigator |4 oth | |
| 700 | 1 | |a Iida, Tomohiro |e investigator |4 oth | |
| 700 | 1 | |a Wakugawa, Sorako |e investigator |4 oth | |
| 700 | 1 | |a Miyara, Yasunori |e investigator |4 oth | |
| 700 | 1 | |a Terao, Nobuhiro |e investigator |4 oth | |
| 700 | 1 | |a Koizumi, Hideki |e investigator |4 oth | |
| 700 | 1 | |a Tanaka, Koji |e investigator |4 oth | |
| 700 | 1 | |a Onoe, Hajime |e investigator |4 oth | |
| 700 | 1 | |a Wakatsuki, Yu |e investigator |4 oth | |
| 700 | 1 | |a Mori, Ryusaburo |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie |d 1985 |g 262(2024), 1 vom: 30. Jan., Seite 43-51 |w (DE-627)NLM01296803X |x 1435-702X |7 nnns |
| 773 | 1 | 8 | |g volume:262 |g year:2024 |g number:1 |g day:30 |g month:01 |g pages:43-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00417-023-06222-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 262 |j 2024 |e 1 |b 30 |c 01 |h 43-51 | ||